

# ABC Farmaceutici, and Alkem Laboratories are Key Players in the Global Primary Biliary Cholangitis Therapeutics Market

*Primary Biliary Cholangitis Therapeutics Market Size, Share and Trend Analysis Report : Global Opportunity Analysis and Industry Forecast, 2023-2032*

WILMINGTON, DELAWARE , UNITED STATES, April 5, 2024

/EINPresswire.com/ -- Allied Market Research published a report, titled,


"[Primary Biliary Cholangitis](#)

[Therapeutics Market](#) by Drug Type

(Primary Drug and Secondary Drug),

and Distribution Channel (Hospital

Pharmacies, Drugs Stores and Retail Pharmacies, and Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2023–2032" According to the report, the global [primary biliary cholangitis therapeutics](#) industry generated \$0.68 billion in 2022 and is anticipated to generate \$1.36 billion by 2032, witnessing a CAGR of 7.1% from 2023 to 2032.



Primary Biliary Cholangitis Therapeutics Market

“

The primary biliary cholangitis therapeutics market size was valued at \$683.95 million in 2022, and is estimated to reach \$1.4 billion by 2032, growing at a CAGR of 7.1% from 2023 to 2032. ”

*Allied Market Research*

□□□□□□□ □□□□□□ □□□□ □□ □□□□□□□:

<https://www.alliedmarketresearch.com/request-sample/A108539>

The global market for primary biliary cholangitis therapeutics is experiencing growth propelled by heightened awareness of the disease in developing nations, an increased demand for treatments, and a surge in research and development efforts. However, obstacles such as delayed diagnosis and limited treatment choices impede this growth. Nevertheless, the implementation of

strategic initiatives by key industry players and a rise in clinical trials for potential treatments present promising prospects for market expansion in the forecast period.

Primary drug segment dominated the global primary biliary cholangitis therapeutics market, contributing to over four-fifths of the total revenue and is anticipated to retain its dominance throughout the forecast period. This leadership position is attributed to the increasing adoption of primary drugs for treating primary biliary cholangitis (PBC). Furthermore, this segment is expected to witness the highest compound annual growth rate (CAGR) of 7.3% from 2023 to 2032, driven by the ongoing research and development activities focusing on primary drugs and their proven efficacy in combating PBC.

Drug stores and retail pharmacies emerged as the leading distribution channel, contributing to nearly three-fifths of the total revenue in the global primary biliary cholangitis therapeutics market. This dominance can be attributed to robust sales in drug stores and the widespread reliance of individuals on these outlets for primary biliary cholangitis medications. However, online pharmacies are anticipated to witness the fastest compound annual growth rate (CAGR) of 8.6% from 2023 to 2032. This segment is poised to dominate the market during the forecast period due to the convenience of online shopping, the surge in e-commerce transactions, attractive discounts and offers, and the ease of payment options.

North America emerged as the leading region in terms of revenue within the global primary biliary cholangitis therapeutics market, capturing more than two-fifths of the total share. This was driven by the region's robust healthcare infrastructure, the presence of key industry players, and an uptick in healthcare spending. However, the Asia-Pacific region is poised to witness the swiftest compound annual growth rate (CAGR) of 8.5% from 2023 to 2032. It is expected to assume market dominance during the forecast period due to the increasing incidence of primary biliary cholangitis, unmet medical needs, and a sizable population base.

Key players operating in the global primary biliary cholangitis therapeutics market include:

- ABC Farmaceutici S.p.a.
- Alkem Laboratories Limited
- AMAGEN INDIA LIFE SCIENCES
- GENFIT
- Intercept Pharmaceuticals, Inc.
- Ipsen Pharma
- Leeford Healthcare Ltd
- Lupin
- Sun Pharmaceutical Industries Ltd.
- Zydus Lifesciences Limited

For more information, visit <https://www.alliedmarketresearch.com/purchase-enquiry/5629>

North America emerged as the leading region in terms of revenue within the global primary biliary cholangitis therapeutics market, capturing more than two-fifths of the total share.

This was driven by the region's robust healthcare infrastructure, the presence of key industry players, and an uptick in healthcare spending. However, the Asia-Pacific region is poised to witness the swiftest compound annual growth rate (CAGR) of 8.5% from 2023 to 2032. It is expected to assume market dominance during the forecast period due to the increasing incidence of primary biliary cholangitis, unmet medical needs, and a sizable population base.

Key players operating in the global primary biliary cholangitis therapeutics market include:

- ABC Farmaceutici S.p.a.
- Alkem Laboratories Limited
- AMAGEN INDIA LIFE SCIENCES
- GENFIT
- Intercept Pharmaceuticals, Inc.
- Ipsen Pharma
- Leeford Healthcare Ltd
- Lupin
- Sun Pharmaceutical Industries Ltd.
- Zydus Lifesciences Limited

□□□ □□□□□□□□ □□ □□□ □□□□□

On the basis of drug type, the primary drug segment held the largest share in the primary biliary cholangitis therapeutics market analysis in 2022.

On the basis of distribution channel, the drugs stores and retail pharmacies dominated the market in 2022.

On the basis of region, Asia-Pacific is expected to witness the highest CAGR during the forecast period.

□□□ □□□□□□□□ □□□ □□□□□□□□□□□□

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the primary biliary cholangitis therapeutics market analysis from 2022 to 2032 to identify the prevailing primary biliary cholangitis therapeutics market opportunity.

The market research is offered along with information related to key drivers, restraints, and opportunities.

Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

In-depth analysis of the primary biliary cholangitis therapeutics market segmentation assists to determine the prevailing market opportunities.

Major countries in each region are mapped according to their revenue contribution to the global market.

Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

The report includes the analysis of the regional as well as global primary biliary cholangitis therapeutics market trends, key players, market segments, application areas, and market growth strategies.

David Correa

Allied Market Research

+1 5038946022

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/701361533>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

